Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells
Sponsor:
Uppsala University Hospital
Location:
Uppsala University Hospital
Uppsala, Sweden, SE-75185
Country:
Sweden The main hypothesis of the investigators performing this study is that the development of autoimmune diabetes might be halted at diagnosis by the immune modulatory properties of mesenchymal stem cells.
Eligible Ages for Trial:
18-40
Eligible Genders for Trial:
Both
Illness:
Diabetes Inclusion Criteria:
- Mentally stable and able to comply with the procedures of the study protocol
- Ability to provide written informed consent
- Clinical history compatible with type 1 diabetes diagnosed less than 10 days of enrolment Stimulate c-peptide >0.1 nmol/l
Exclusion Criteria:
- Patients with BMI>30
- Patients with active infections, unless treatment is not judged necessary by the investigators
- Patients with unstable cardiovascular status
- Patients with serological evidence of infection with HIV, hepatitis B or hepatitis C.
- Sexually active females who are not a) postmenopausal, b) surgically sterile or c) using an acceptable method of contraception: oral contraceptives, Norplant, Depo-provera and barrier devices combined with spermicidal gel are acceptable.
- Patients with known or previous malignancy. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with autologous MSC.
March 1, 2010 - January 1, 2012
Trial Status:
Recruiting Contact:
Per-Ola Carlsson, MD, PhD +46 18 471 4425 Per-Ola.Carlsson@mcb.uu.se

